You are here

ALS

FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit

FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit

MedCity News

BrainStorm Cell Therapeutics

stem cell therapy

clinical trials

Flag link:

Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway

Despite red flag from FDA, controversial ALS cell therapy developer says it may still march ahead anyway

Endpoints

BrainStorm Cell Therapeutics

Flag link:

Stem cell therapy for ALS fails a large clinical trial

Stem cell therapy for ALS fails a large clinical trial

BioPharma Dive

clinical trials

BrainStorm Therapeutics

Flag link:

Bristol Myers, insitro ally to apply machine learning to ALS R&D

Bristol Myers, insitro ally to apply machine learning to ALS R&D

Fierce Biotech

Bristol-Myers Squibb

machine learning

artificial intelligence

Flag link:

Early signs of survival benefit raise optimism around a small biotech's ALS drug

Early signs of survival benefit raise optimism around a small biotech's ALS drug

BioPharma Dive

Amylyx Pharmaceuticals

Flag link:

Biogen teams up with gene-editing startup Scribe on ALS program

Biogen teams up with gene-editing startup Scribe on ALS program

Pharmaforum

Scribe Therapeutics

Flag link:

Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines

Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines

Forbes

Jennifer Doudna

Scribe Therapeutics

Flag link:

Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders

Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders

Xconomy

Libra Therapeutics

Flag link:

After a rare win, a biotech details long-awaited results for its ALS drug

After a rare win, a biotech details long-awaited results for its ALS drug

BioPharma Dive

Flag link:

Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

BioSpace

clinical trials

Flag link:

Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work

Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work

Fierce Biotech

Amylyx Pharmaceuticals

Alzheimer's disease

Flag link:

Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

BioSpace

Yumanity Therapeutics

frontotemporal lobar dementia

Flag link:

After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug

After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug

BioSpace

Denali Therapeutics

Alzheimer's disease

clinical trials

Flag link:

Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments

Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments

BioSpace

Flag link:

I Have a Dream… Five Dreams for Biotech

I Have a Dream… Five Dreams for Biotech

BioSpace

Alzheimer's disease

Flag link:

Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Yahoo/Zacks.com

clinical trials

Flag link:

First-of-its-kind trial in ALS spurs hope for brutal disease

First-of-its-kind trial in ALS spurs hope for brutal disease

BioPharma Dive

clinical trials

Implicit Bioscience

Prilenia Therapeutics

Clene Nanomedicine

Flag link:

5 years later, Ice Bucket Challenge's impact on drug research still unfolding

5 years later, Ice Bucket Challenge's impact on drug research still unfolding

Bizjournals

drug development

Flag link:

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

Endpoints

Flag link:

Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns

Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns

BioSpace

clinical trials

H.P. Acthar Gel

Flag link:

Pages